EBITDA
The latest quarterly ebitda is $153.90 Million with a quarter-over-quarter change of -19.17%. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) measures a company's operating performance by removing non-cash charges and capital structure effects.
PODD EBITDA
Reported quarterly EBITDA; no daily interpolation.
PODD Quarterly EBITDA Growth (YoY)
EBITDA growth vs the same quarter one year earlier, last 20 quarters.
Current EBITDA
$153.90M
$153.90 Million
Quarter-over-Quarter Change
-19.17%
vs. $190.40M prior quarter
Historical Data
85
Quarters of data available
Quarterly EBITDA History
| Period | EBITDA | QoQ Change | % Change |
|---|---|---|---|
| Q1 2026 | $153.90M | $-36.50M | -19.17% |
| Q4 2025 | $190.40M | +$30.00M | +18.70% |
| Q3 2025 | $160.40M | +$90.10M | +128.17% |
| Q2 2025 | $70.30M | $-8.70M | -11.01% |
| Q1 2025 | $79.00M | $-62.50M | -44.17% |
| Q4 2024 | $141.50M | +$25.00M | +21.46% |
| Q3 2024 | $116.50M | +$35.20M | +43.30% |
| Q2 2024 | $81.30M | $-3.10M | -3.67% |
| Q1 2024 | $84.40M | $-48.90M | -36.68% |
| Q4 2023 | $133.30M | +$50.50M | +60.99% |
| Q3 2023 | $82.80M | +$26.50M | +47.07% |
| Q2 2023 | $56.30M | +$5.10M | +9.96% |
| Q1 2023 | $51.20M | +$4.60M | +9.87% |
| Q4 2022 | $46.60M | +$27.20M | +140.21% |
| Q3 2022 | $19.40M | +$31.60M | +259.02% |
| Q2 2022 | $-12.20M | $-64.70M | -123.24% |
| Q1 2022 | $52.50M | $-10.10M | -16.13% |
| Q4 2021 | $62.60M | +$17.40M | +38.50% |
| Q3 2021 | $45.20M | +$42.80M | +1783.33% |
| Q2 2021 | $2.40M | $-23.50M | -90.73% |
| Q1 2021 | $25.90M | +$6.70M | +34.90% |
| Q4 2020 | $19.20M | $-16.30M | -45.92% |
| Q3 2020 | $35.50M | $-2.90M | -7.55% |
| Q2 2020 | $38.40M | +$21.20M | +123.26% |
| Q1 2020 | $17.20M | $-8.94M | -34.21% |
| Q4 2019 | $26.14M | +$8.54M | +48.54% |
| Q3 2019 | $17.60M | +$2.80M | +18.92% |
| Q2 2019 | $14.80M | $-900,000 | -5.73% |
| Q1 2019 | $15.70M | $-6.43M | -29.05% |
| Q4 2018 | $22.13M | +$9.97M | +81.96% |
| Q3 2018 | $12.16M | +$3.19M | +35.54% |
| Q2 2018 | $8.97M | +$3.77M | +72.41% |
| Q1 2018 | $5.20M | +$2.10M | +67.93% |
| Q4 2017 | $3.10M | $-3.33M | -51.80% |
| Q3 2017 | $6.43M | +$5.92M | +1150.78% |
| Q2 2017 | $514,000 | +$2.06M | +133.14% |
| Q1 2017 | $-1.55M | $-1.09M | -236.44% |
| Q4 2016 | $-461,000 | $-4.17M | -112.44% |
| Q3 2016 | $3.71M | +$1.44M | +63.74% |
| Q2 2016 | $2.26M | +$6.37M | +155.13% |
| Q1 2016 | $-4.11M | +$15.50M | +79.06% |
| Q4 2015 | $-19.61M | $-9.13M | -87.08% |
| Q3 2015 | $-10.48M | $-132,000 | -1.28% |
| Q2 2015 | $-10.35M | $-6.54M | -171.94% |
| Q1 2015 | $-3.81M | $-4.64M | -553.64% |
| Q4 2014 | $839,000 | +$5.55M | +117.80% |
| Q3 2014 | $-4.71M | +$17.34M | +78.63% |
| Q2 2014 | $-22.05M | $-23.53M | -1590.14% |
| Q1 2014 | $1.48M | $-3.06M | -67.38% |
| Q4 2013 | $4.54M | +$18.73M | +131.97% |
| Q3 2013 | $-14.19M | $-10.94M | -336.48% |
| Q2 2013 | $-3.25M | +$24,000 | +0.73% |
| Q1 2013 | $-3.27M | $-154,000 | -4.93% |
| Q4 2012 | $-3.12M | +$2.73M | +46.61% |
| Q3 2012 | $-5.85M | +$2.00M | +25.44% |
| Q2 2012 | $-7.84M | +$182,000 | +2.27% |
| Q1 2012 | $-8.02M | $-470,000 | -6.22% |
| Q4 2011 | $-7.55M | $-652,000 | -9.45% |
| Q3 2011 | $-6.90M | +$6.29M | +47.69% |
| Q2 2011 | $-13.19M | $-7.12M | -117.22% |
| Q1 2011 | $-6.07M | $-1.91M | -45.88% |
| Q4 2010 | $-4.16M | +$2.87M | +40.77% |
| Q3 2010 | $-7.03M | +$1.61M | +18.68% |
| Q2 2010 | $-8.64M | +$650,000 | +7.00% |
| Q1 2010 | $-9.29M | +$1.45M | +13.49% |
| Q4 2009 | $-10.74M | +$1.37M | +11.30% |
| Q3 2009 | $-12.11M | +$3.01M | +19.91% |
| Q2 2009 | $-15.12M | +$1.05M | +6.47% |
| Q1 2009 | $-16.17M | +$9.48M | +36.96% |
| Q4 2008 | $-25.65M | $-7.59M | -42.06% |
| Q3 2008 | $-18.05M | +$2.02M | +10.07% |
| Q2 2008 | $-20.07M | $-1.48M | -7.95% |
| Q1 2008 | $-18.60M | $-3.93M | -26.81% |
| Q4 2007 | $-14.66M | $-1.48M | -11.19% |
| Q3 2007 | $-13.19M | $-2.01M | -18.00% |
| Q2 2007 | $-11.18M | $-1.28M | -12.99% |
| Q1 2007 | $-9.89M | $-1.46M | -17.26% |
| Q4 2006 | $-8.44M | +$1.10M | +11.51% |
| Q3 2006 | $-9.53M | $-10.21M | -1514.39% |
| Q2 2006 | $674,000 | +$0 | 0.00% |
| Q1 2006 | $674,000 | +$674,000 | — |
| Q4 2005 | $0 | +$0 | — |
| Q3 2005 | $0 | +$0 | — |
| Q2 2005 | $0 | +$0 | — |
| Q1 2005 | $0 | — | — |
About Insulet Corp.
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Ashley A. McEvoy